^
    Back
    Association details:
    Biomarker:BCL2L1 underexpression
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    volasertib (NBL-001) (PLK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

    Published date:
    11/06/2019
    Excerpt:
    ABT-199-sensitive cell lines showed lower Bcl-xL mRNA levels irrespective of their Bcl-2 expression, and displayed synergy with BI-6727. 
    DOI:
    https://doi.org/10.1182/blood-2019-129823